- Home
- BMRN vs LLYVA Comparison
BMRN vs LLYVA Comparison
Compare BMRN & LLYVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- LLYVA
- Stock Information
- Founded
- BMRN 1996
- LLYVA 1991
- Country
- BMRN United States
- LLYVA United States
- Employees
- BMRN N/A
- LLYVA N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- LLYVA Broadcasting
- Sector
- BMRN Health Care
- LLYVA Industrials
- Exchange
- BMRN Nasdaq
- LLYVA Nasdaq
- Market Cap
- BMRN 10.0B
- LLYVA 8.3B
- IPO Year
- BMRN 1999
- LLYVA N/A
- Fundamental
- Price
- BMRN $52.47
- LLYVA $85.56
- Analyst Decision
- BMRN Buy
- LLYVA
- Analyst Count
- BMRN 18
- LLYVA 0
- Target Price
- BMRN $93.71
- LLYVA N/A
- AVG Volume (30 Days)
- BMRN 2.2M
- LLYVA 120.9K
- Earning Date
- BMRN 10-28-2025
- LLYVA 01-01-0001
- Dividend Yield
- BMRN N/A
- LLYVA N/A
- EPS Growth
- BMRN 154.69
- LLYVA N/A
- EPS
- BMRN 3.40
- LLYVA N/A
- Revenue
- BMRN $3,063,608,000.00
- LLYVA N/A
- Revenue This Year
- BMRN $13.35
- LLYVA N/A
- Revenue Next Year
- BMRN $9.18
- LLYVA $11.45
- P/E Ratio
- BMRN $15.44
- LLYVA N/A
- Revenue Growth
- BMRN 18.36
- LLYVA N/A
- 52 Week Low
- BMRN $51.57
- LLYVA $52.32
- 52 Week High
- BMRN $73.51
- LLYVA $99.63
- Technical
- Relative Strength Index (RSI)
- BMRN 38.26
- LLYVA 32.20
- Support Level
- BMRN $51.79
- LLYVA $83.85
- Resistance Level
- BMRN $55.39
- LLYVA $87.27
- Average True Range (ATR)
- BMRN 1.36
- LLYVA 2.02
- MACD
- BMRN -0.11
- LLYVA -0.81
- Stochastic Oscillator
- BMRN 19.28
- LLYVA 14.17
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About LLYVA Liberty Media Corporation Series A Liberty Live
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.